Multi Center Prospective Registry of Infliximab Use for Childhood Uveitis

Chronic Uveitis Clinical Trial

Official title:

Multi Center Prospective Registry of Infliximab Use for Childhood Uveitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00589628
• Other study ID #: Pro00000057
• Status: Completed
• Phase: Phase 4
• First received: December 27, 2007
• Last updated: August 22, 2013
• Start date: September 2007
• Est. completion date: December 2010

Study information

• Verified date: August 2013
• Source: Duke University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to examine the efficacy of infliximab for the treatment of persistent uveitis in children. Participants (4-18 years of age) will be randomly assigned to either 5mg/kg or 10mg/kg dose of infliximab to be administered by intravenous infusion at four week intervals. Participant responses will be measured at at four to eight week intervals for up to ten months.

Description:

Pediatric rheumatologists often use infliximab in the treatment of childhood uveitis, at this time there are no prospective studies for this use. Participants will be randomized to initial suggested dose of infliximab (5 mg/kg/dose vs 10 mg/kg/dose) and data will be collected prospectively with regard to ophthalmologic outcomes. Study participants will be followed for up to 10 months to determine efficacy and side effects, and an additional 30 days for safety reports. Descriptive statistics will be gathered on participant demographics, uveitis characteristics, change in immunosuppressive medications, number of responders, ophthalmologic measures and change in corticosteroid dose during the study period. Initial to final dose will be examined by paired t-test. The proportion of responders in the 5 mg/kg initial dose group will be compared to the 10 mg/kg/dose by a Chi-square or Fisher's exact test, depending on numbers available. Predictors of response will be examined by logistic regression.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 13
• Est. completion date: December 2010
• Est. primary completion date: December 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 4 Years to 18 Years

Eligibility

Inclusion Criteria:.

1. Ages 4 to 18 years old,

2. Non-infectious uveitis

3. Persistent uveitis uncontrolled by topical medications, or unacceptable side effects of topical medications.

4. Failure of at least six weeks of treatment with a non-biological disease modifying agent such as methotrexate, cyclosporine, mycophenolate mofetil, or azathioprine.

5. Ability to provide informed consent (subject or parent/guardian)

6. Onset of uveitis < 16 years of age.

7. Topical ophthalmologic treatments allowed.

8. Systemic corticosteroid use at entry may be allowed.

9. Willingness to use acceptable contraception if sexually active for the duration of the study and for 6 months after receiving the last infliximab infusion.

10. Concomitant methotrexate must be taken at time of initiation of infliximab

11. Participant must be able to cooperate for a non-sedated slit lamp exam and visual acuity examination.

12. Negative Purified Protein Derivative (PPD) placed and read within 1 month of initiation of infliximab

13. The screening laboratory test results must meet the following criteria:

• WBC (white blood cell count): within normal range for institution

• ANC (absolute neutrophil count): within normal range for institution

• Hemoglobin: greater than 10 grams/deciliter

• Platelets: within normal range for institution

• Serum Creatinine: within normal range for age

• AST - aspartate aminotransferase - within normal range for institution

• ALT - alanine aminotransferase- within normal range for institution

Exclusion Criteria:

1. Previous use of biologic medications for uveitis.

2. Intraocular steroid injection or ophthalmologic surgery within the preceding 3 months.

3. Uveitis due to trauma or intraocular surgery

4. Females who are pregnant, nursing, or planning pregnancy within 6 months after the last infliximab infusion.

5. Males who plan on fathering a child within 6 months after their last infliximab infusion.

6. A history of a known allergy to murine products.

7. Documentation of seropositivity for human immunodeficiency virus (HIV).

8. Documentation of a positive test for hepatitis B surface antigen or hepatitis C

9. A known history of a serious infection (e.g., hepatitis, pneumonia, or pyelonephritis) in the previous 3 months.

10. An opportunistic infection (e.g., herpes zoster [shingles], cytomegalovirus, Pneumocystis carinii, aspergillosis, histoplasmosis, or mycobacteria other than TB) within 6 months prior to screening.

11. A concomitant diagnosis or history of congestive heart failure.

12. A history of lymphoproliferative disease.

13. Any known malignancy or a history of malignancy.

14. Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, or cerebral disease.

15. Use of any investigational drug within 30 days prior to screening or within five half-lives of the first dose of the investigational agent, whichever is longer.

16. Presence of a transplanted solid organ.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Chronic Uveitis
• Uveitis

Intervention

Drug:
• infliximab
5mg/kg/dose IV at 4 week intervals
• infliximab
10mg/kg/dose IV at 4 week intervals

Locations

Country	Name	City	State
United States	Duke University Medical Center	Durham	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
Egla C. Rabinovich	Childhood Arthritis and Rheumatology Research Alliance

Country where clinical trial is conducted

United States, 

References & Publications (5)

Ardoin SP, Kredich D, Rabinovich E, Schanberg LE, Jaffe GJ. Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up. Am J Ophthalmol. 2007 Dec;144(6):844-849. Epub 2007 Oct 22. — View Citation

Heiligenhaus A, Foeldvari I, Edelsten C, Smith JR, Saurenmann RK, Bodaghi B, de Boer J, Graham E, Anton J, Kotaniemi K, Mackensen F, Minden K, Nielsen S, Rabinovich EC, Ramanan AV, Strand V; Multinational Interdisciplinary Working Group for Uveitis in Childhood. Proposed outcome measures for prospective clinical trials in juvenile idiopathic arthritis-associated uveitis: a consensus effort from the multinational interdisciplinary working group for uveitis in childhood. Arthritis Care Res (Hoboken). 2012 Sep;64(9):1365-72. doi: 10.1002/acr.21674. Review. — View Citation

Kahn P, Weiss M, Imundo LF, Levy DM. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology. 2006 May;113(5):860-4.e2. Epub 2006 Mar 20. — View Citation

Rajaraman RT, Kimura Y, Li S, Haines K, Chu DS. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology. 2006 Feb;113(2):308-14. Epub 2006 Jan 10. — View Citation

Saurenmann RK, Levin AV, Rose JB, Parker S, Rabinovitch T, Tyrrell PN, Feldman BM, Laxer RM, Schneider R, Silverman ED. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford). 2006 Aug;45(8):982-9. Epub 2006 F — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Effects of Infliximab on Uveitis Disease Activity.	Number of subjects with improvement in uveitis, defined as a two step decrease in level of inflammation (as defined by SUN criteria, AC cells, vitreous haze) or decrease to grade 0. A grading scheme of 0 indicating (<1 cell/ocular field) low levels of inflammation to 4+ indicating (>50 cells/ocular field) indicating high levels of inflammation.	9 months	No

External Links

•   Research Information. Click on current studies